摘要
目的 探讨贝伐珠单抗、卡培他滨联合奥沙利铂对结直肠癌患者的疗效。方法 选择新密市第一人民医院收治的70例结直肠癌患者作为本研究对象,研究对象纳入时间为2020年1月至2022年1月,所有患者均接受结直肠癌根治术治疗。根据术后化疗联合方案将患者分为对照组和化疗联合组。对照组接受XELOX化疗方案(卡培他滨联合奥沙利铂),化疗联合组在XELOX化疗方案的基础上增加贝伐珠单抗。21 d为1个化疗周期,两组患者均治疗2个疗程。疗程结束后对比两组疾病控制率、血清肿瘤标志物水平、生活质量以及不良反应发生情况。结果 化疗联合组疾病控制率高于对照组(P<0.05);化疗结束后化疗联合组癌症治疗功能评价量表(FACT-CR)评分高于对照组(P<0.05);化疗结束后化疗联合组血清癌胚抗原(CEA)和糖类抗原19-9(CA19-9)水平均低于对照组(P<0.05);化疗联合组胃肠道反应、骨髓抑制、口腔炎、周围神经毒性、白细胞计数降低发生例数略高于对照组,但两组差异无统计学意义(P>0.05)。结论 贝伐珠单抗、卡培他滨联合奥沙利铂有助于结直肠癌患者控制病情发展,降低血清CEA、CA19-9等肿瘤标志物水平,改善患者生活质量,且不良反应不明显。
Objective To investigate the effects of bevacizumab, capecitabine combined with oxaliplatin in patients with colorectal cancer.Methods A total of 70 cases of colorectal cancer admitted to Xinmi First People’s Hospital were selected as the research subjects for this study. The research subjects were included from January 2020 to January 2022. All patients underwent radical resection for colorectal cancer. The subjects were divided into the control group and the chemotherapy combination group according to postoperative chemotherapy combination regimens. The control group received XELOX chemotherapy(capecitabine and oxaliplatin), and the chemotherapy combination group received bevacizumab on the basis of XELOX chemotherapy. Twenty-one days was a cycle of chemotherapy, and patients in both groups were treated for 2 cycles of treatment. After the course of treatment, the disease control rate, serum tumor marker levels, quality of life and adverse reactions were compared between the two groups.Results The disease control rate in the chemotherapy combination group was higher than that in the control group(P<0.05). After chemotherapy, the functional assessment of cancer therapy-colorectum(FACT-CR) score of the chemotherapy combination group was higher than that of the control group(P<0.05). Serum carcinoembryonic antigen(CEA) and carbohydrate antigen 19-9(CA19-9) levels in chemotherapy combination group were lower than those in control group after chemotherapy(P<0.05). Gastrointestinal reaction, bone marrow suppression, stomatitis, peripheral neurotoxicity in chemotherapy combination group, low white blood cell count was slightly higher than the control group, but there were no significant differences between the two groups(P>0.05).Conclusion Bevacizumab, capecitabine combined with oxaliplatin can help patients with colorectal cancer to control the progression of the disease, reduce the levels of serum CEA, CA19-9 and other tumor markers, improve the quality of life of patients, and the adverse reactions are not obviou
作者
梁盟
陈新平
王涵博
LIANG Meng;CHEN Xinping;WANG Hanbo(Department of Oncology,Xinmi First People’s Hospital,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2023年第1期129-131,共3页
Henan Medical Research
